CO4940466A1 - Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas - Google Patents

Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas

Info

Publication number
CO4940466A1
CO4940466A1 CO97022872A CO97022872A CO4940466A1 CO 4940466 A1 CO4940466 A1 CO 4940466A1 CO 97022872 A CO97022872 A CO 97022872A CO 97022872 A CO97022872 A CO 97022872A CO 4940466 A1 CO4940466 A1 CO 4940466A1
Authority
CO
Colombia
Prior art keywords
salts
piperazinyl
dihydro
ethyl
benzoisotiazol
Prior art date
Application number
CO97022872A
Other languages
English (en)
Inventor
Frank Robert Busch
Anne Rose Carol
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4940466A1 publication Critical patent/CO4940466A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

La invención se refiere a las sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2H-indol-2-ona dihidratadas, a composiciones farmacéuticas que contienen dichas sales metanosulfonato dihidratadas, y a procedimientos de uso de dichas sales metanosulfonato dihidratadas para tratar trastornos psicóticos.
CO97022872A 1996-05-07 1997-04-29 Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas CO4940466A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
CO4940466A1 true CO4940466A1 (es) 2000-07-24

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97022872A CO4940466A1 (es) 1996-05-07 1997-04-29 Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas

Country Status (41)

Country Link
US (1) US6245765B1 (es)
EP (1) EP0918772B1 (es)
JP (1) JP3494659B2 (es)
KR (1) KR100333215B1 (es)
CN (1) CN1091769C (es)
AP (1) AP765A (es)
AR (1) AR007004A1 (es)
AT (1) ATE278689T1 (es)
AU (1) AU731267B2 (es)
BG (1) BG63544B1 (es)
BR (1) BR9709889A (es)
CA (1) CA2252898C (es)
CO (1) CO4940466A1 (es)
CZ (1) CZ289215B6 (es)
DE (1) DE69731094T2 (es)
DK (1) DK0918772T3 (es)
DZ (1) DZ2222A1 (es)
EA (1) EA001190B1 (es)
EG (1) EG24076A (es)
ES (1) ES2229342T3 (es)
GT (1) GT199700052A (es)
HK (1) HK1017892A1 (es)
HR (1) HRP970236B1 (es)
ID (1) ID16867A (es)
IL (1) IL126591A (es)
IS (1) IS2080B (es)
MA (1) MA24171A1 (es)
MY (1) MY119997A (es)
NO (1) NO312514B1 (es)
NZ (1) NZ332218A (es)
OA (1) OA10909A (es)
PL (1) PL188330B1 (es)
PT (1) PT918772E (es)
SI (1) SI0918772T1 (es)
SK (1) SK282837B6 (es)
TN (1) TNSN97074A1 (es)
TR (1) TR199802240T2 (es)
TW (1) TW491847B (es)
UA (1) UA46840C2 (es)
WO (1) WO1997042191A1 (es)
ZA (1) ZA973876B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
KR20030007824A (ko) * 2000-06-02 2003-01-23 화이자 프로덕츠 인크. 정신의학적 장애 및 안질환의 치료를 위한ｓ-메틸-디히드로-지프라시돈
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
WO2005035531A1 (en) 2003-06-03 2005-04-21 Teva Paharmaceutical Industries Ltd. POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
US20060258679A1 (en) * 2005-02-11 2006-11-16 Alex Mainfeld Process of preparing ziprasidone mesylate
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
WO2012053654A1 (en) * 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
NZ332219A (en) 1996-05-07 2005-02-25 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone), its preparation and its use as dopamine D2 antagonist

Also Published As

Publication number Publication date
BR9709889A (pt) 1999-08-10
DE69731094D1 (de) 2004-11-11
MY119997A (en) 2005-08-30
AP9700976A0 (en) 1997-07-31
DK0918772T3 (da) 2005-01-10
DZ2222A1 (fr) 2002-12-03
SI0918772T1 (en) 2005-02-28
PL188330B1 (pl) 2005-01-31
EP0918772B1 (en) 2004-10-06
TR199802240T2 (es) 1999-02-22
GT199700052A (es) 2001-08-29
CA2252898A1 (en) 1997-11-13
BG102892A (en) 1999-09-30
AR007004A1 (es) 1999-10-13
ID16867A (id) 1997-11-20
IL126591A (en) 2001-11-25
EA001190B1 (ru) 2000-12-25
CZ349398A3 (cs) 1999-09-15
PT918772E (pt) 2004-12-31
CN1091769C (zh) 2002-10-02
EA199800912A1 (ru) 1999-04-29
AP765A (en) 1999-09-17
IL126591A0 (en) 1999-08-17
NO985194D0 (no) 1998-11-06
HRP970236A2 (en) 1998-06-30
TW491847B (en) 2002-06-21
WO1997042191A1 (en) 1997-11-13
NO985194L (no) 1998-11-06
HRP970236B1 (en) 2002-12-31
NO312514B1 (no) 2002-05-21
BG63544B1 (bg) 2002-04-30
ES2229342T3 (es) 2005-04-16
EP0918772A1 (en) 1999-06-02
DE69731094T2 (de) 2006-02-23
EG24076A (en) 2008-05-11
UA46840C2 (uk) 2002-06-17
KR100333215B1 (ko) 2002-06-20
IS2080B (is) 2006-02-15
TNSN97074A1 (fr) 2005-03-15
AU731267B2 (en) 2001-03-29
CZ289215B6 (cs) 2001-12-12
OA10909A (en) 2001-10-26
IS4874A (is) 1998-10-20
JP3494659B2 (ja) 2004-02-09
CA2252898C (en) 2003-04-08
KR20000010824A (ko) 2000-02-25
ATE278689T1 (de) 2004-10-15
SK150898A3 (en) 2000-02-14
NZ332218A (en) 2005-02-25
AU2174797A (en) 1997-11-26
US6245765B1 (en) 2001-06-12
ZA973876B (en) 1998-11-06
CN1216991A (zh) 1999-05-19
PL329884A1 (en) 1999-04-12
HK1017892A1 (en) 1999-12-03
SK282837B6 (sk) 2002-12-03
MA24171A1 (fr) 1997-12-31
JPH11509867A (ja) 1999-08-31

Similar Documents

Publication Publication Date Title
CO4940466A1 (es) Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas
CO4940465A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
ATE420876T1 (de) Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
TR200200068T2 (tr) Nematisital triflüorobütenler
NO982907D0 (no) Tyrosinderivater som <alfa>-v-integrininhibitorer
BR9811099A (pt) Inibidores de urocinase
DE60121461D1 (de) Kondensierte pyridoindolderivate
NO180445C (no) 2-(4-hydroksypiperidino)-1-alkanol-derivater som anti-iskemiske midler
ES2154318T3 (es) Agentes antitromboticos.
HN2001000235A (es) Derivados puentes de piperazina
ATE219067T1 (de) Substituierte (2-(1-piperazinyl)ethoxy)methyl- derivate
RS51003B (sr) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
DE60112960D1 (de) Kondensierte pyridoindolderivate
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
PT790236E (pt) Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
NO940274D0 (no) 2-(4-(-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DK0888340T3 (da) 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carboxylsyre-derivater som antagonister for enodthelin
AR027349A1 (es) Derivados de amidas heterociclicas
MX9205186A (es) Derivados de 4-[4-[4-(4-hidroxifenil)-1-piperazinil]-fenil]-5-metil-3h-1,2,4-triazo l-3-ona
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli